StemCell Therapy

A Cambridge biotech that wants to develop tailor-made medicines for cancers and diseases of the immune system said Thursday it has raised $168 million in venture funding, bringing the startups total capital to $386 million after 16 months of recruiting investors.

Odyssey Therapeutics will use the money to advance a portfolio of drugs to treat solid tumors and immune disorders, such as inflammatory bowel disease, rheumatoid arthritis, and lupus, according to the startups founder and chief executive, Gary D. Glick. The firm of 160 employees is housed in temporary quarters on Binney Street in Kendall Square and plans to move to Sleeper Street in Bostons Seaport District in early December.

Odyssey has eight drug development programs that rely on the cutting-edge approach known as precision medicine. In contrast to the one-size-fits-all design of most drugs, precision medicine, sometimes called personalized medicine, takes into account differences in peoples genes, environments, and lifestyles when creating medications.

The startup is using artificial intelligence and machine learning, among other tools, to discover and develop drugs. And it is focusing on serious, common diseases with few, if any, effective treatments, unlike the Massachusetts biotechs working on medicines for rare disorders drugs that can carry six- and even seven-figure price tags.

Were not looking to market and commercialize in what has historically been thought of as rare or orphan diseases, Glick said.

The latest funding round, Odysseys second, was led by General Catalyst, a 22-year-old Cambridge-based venture capital firm. At least eight investors from the first round ponied up more money for the second, as did a number of new investors, which further validates our approach to therapeutic development, Glick said.

Glick is a serial biotech investor and former longtime chemistry professor at the University of Michigan who founded Boston-based Scorpion Therapeutics and previously co-founded Lycera, another privately held biotech, in Ann Arbor, Mich.

The chair of Odysseys board is Dr. Jeffrey Leiden, the former CEO of Boston-based Vertex Pharmaceuticals, who now serves as executive chairman of its board. Glick said he has known Leiden since around 2009, when the latter was managing director of Clarus Ventures and chaired Lyceras board. He considers Leiden a mentor, saying, There really is no better biotech executive than Jeff.

Leiden said Odyssey has quickly attracted investors because it possesses the three Ts: the team, the targets, and the technologies. It boasts seasoned drug hunters from Novartis and other companies, has pinpointed a promising raft of drug targets, and is deploying technologies ranging from artificial intelligence to the engineering of so-called small molecule drugs medicines made of small chemical molecules and typically dispensed as pills.

I get asked to join the boards of lots of companies, Leiden said. I said yes to this one, he added, because its a very unusual company.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com.

View post:
Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe

Medical oncologist Nina DAbreo, MD, an assistant professor in the Department of Medicine at NYU Long Island School of Medicine, treats people with varying stages of breast cancer. She also sees and counsels women with benign but high-risk breast disease, regarding options to lower their risk.

As medical director of the Breast Medical Oncology Program at Perlmutter Cancer Center at NYU Langone HospitalLong Island, Dr. DAbreo is involved in the creation and implementation of programs that can help at every stage of the continuum of breast cancer carefrom diagnosis to survivorship.

She discusses how she decided to become a doctor, how treatment for breast cancer has changed, and more.

I grew up in Mumbai, India, and my mother was a biology teacher, so science was her thing. She had wanted to become a physician, and for many reasons that wasnt feasible. Growing up, I was good at math, science, and biology, but math and physics were my strong suit. I thought eventually I would study engineering and work in an information technologybased job. My mother, however, wanted me to become a physician, and I was adamant that I wouldnt do that.

In India, the way higher education is structured, scores matter in qualifying exams. And I had scores that qualified me to get into one of the very prestigious medical schools there. Unknown to me at the time, my parents put in an application for medical school, for which, lo and behold, I got an interview. I promised them I would attend a few medical school classes and see how it would go. I attended engineering school for three months and medical school right after, just to see what it was like. After the first anatomy exam, I was hooked. There is a lot of physics involved with the human body. Pharmacology was fantastic, and physiology was really what drew me in. So, after the first three months, we had a short exam and I did well on that. I gave up my admission to engineering school and decided to go with medicine.

The most important advance is personalizing therapy, in which we refine treatment to suit an individual patients tumor biology. We have moved away from the one-size-fits-all style of treatment, which has been the history of breast cancer treatment through the ages, from the times of radical mastectomies to, finally, when medical oncology evolved. Traditionally, we gave a lot of chemotherapy to all patients. We still do this for some patients for the right reasons, but now we are personalizing therapy and tailoring it to fit both the patients biology and their clinical condition. This means that in some cases we add treatment when required and in some cases, we de-escalate. Personalized treatment has evolved in the 14 years that I have been in practice as a medical oncologist, and it continues to be refined.

I am the principal investigator in the NYU Langone network for two exciting cooperative group-led trials looking to optimize how we treat HER2-positive breast cancer. This is an aggressive form of the disease, for which we typically give patients multi-agent chemotherapy in combination with HER2-blocking antibodies before or after surgery. CompassHER2-pCR is a de-escalation trial led by the Eastern Cooperative Oncology Group that is using pathological complete response (pCR) to a single chemotherapy with HER2-targeted drugs given before surgery, to appropriately minimize the use of additional chemotherapy for patients who dont need it.

The second part of that trial, called CompassHER2 RD, is looking at optimizing treatment after surgery. This is for people who do not achieve a complete response and have residual disease (RD). Typically these patients would receive a HER2-targeted drug called TDM-1. In this trial, they can be escalated to TDM-1 in combination with another oral HER2-blocking drug. These are great examples of tailoring therapy based on tumor response so we dont over- or under-treat anyone.

Another area that I am intrigued by is using non-pharmacological approaches to improve cancer care. I think there is a growing interest in the idea that exercise is medicine. Not only can exercise make patients feel better, it can also improve cancer outcomes. We are developing an investigator-initiated project in collaboration with colleagues who are experts in the field of oncological rehabilitation at Perlmutter Cancer Center as well as another academic center, looking at adding exercise for patients with early-stage estrogen receptorpositive breast cancer. These patients will receive a short course of exercise before surgery to see whether that will ultimately impact their cancer outcomes. So this is another way of optimizing cancer therapy, but using exercisea nontoxic, non-pharmacological interventionin combination with hormonal therapy.

There are many success stories that are gratifying both professionally and personally.

Eight years ago, I treated a pregnant patient who was diagnosed with locally advanced HER2-positive breast cancer. At the time, she was underinsured and had trouble finding medical care. With our medical oncology team and our gynecologist we were able to successfully get her through her pregnancy. We now see her with her daughter, who was born right after the treatment, in the clinic. Watching her child grow over the years is extremely gratifying to me. For us, each follow-up visit is a sign of how far weve come and how we were able to, as a team, bring this patient successfully through a time of crisis.

Another story thats professionally gratifying concerns a patient who participated in a clinical trial that looked at using adjuvant therapy, which is treatment after surgery, in patients with triple-negative breast cancer. This was an escalation trial in which immunotherapy was added for patients who had residual disease after receiving chemotherapy and surgery. We were one of the few sites on Long Island offering the trial when it opened.

She came to us from Memorial Sloan Kettering Cancer Center (MSKCC). Even though this patient didnt have access to the trial at the time at MSKCC, her oncologist was able to direct her and she traveled to us and was successfully enrolled. She is now about three years out and is doing very, very well. It may not sound like a big deal, but it was a big leap of faith for this patient to leave MSKCC and come to us for treatment. That experience illustrated how oncology care is truly collaborative. Patients are able to find resources, and we are able to assist them thanks to an excellent network of support.

One advance is in patients who receive estrogen-driven therapy for long durations. We know that some patients receive therapy for 10 years, but there are technologies that might help us assess who among those patients really needs extended therapy. One way to do this is by analyzing circulating tumor DNA and identifying markers in the blood that can then predict whether the cancer is likely to recur. This is an evolving field. There are some applications of this science already in the clinic, for example, in colon cancer, and I think this will also be applicable to breast cancer to further refine how long we treat patients and when to change therapy.

Newer antibodydrug conjugates that are less toxic and use smaller doses of chemotherapy bound to a targeted drug are also on the horizon and may replace traditional chemotherapy.

A fascinating area is personalized vaccines. Breast cancer is also one of the tumor types where using the patients own immune system in many ways, including chimeric antigen receptor (CAR) T cells, is an area of promise. This is particularly relevant in patients with cancers like triple-negative breast cancer, where there are fewer effective treatments.

The one thing that has remained constant, regardless of all the advancements in treatment, is that we are still personalizing cancer care. Its not just that the treatments are personalized, but when someone comes to Perlmutter Cancer Center, they will be cared for by a very personal team, one that they can contact at any time. Our physicians, nurse practitioners, nurses, and medical assistants know the patient, and they become part of a family. This very one-on-one approach is what patients can expect when they see us. Like any other major cancer center, we have the ability to offer technology and cutting-edge trials, but its all done in a very personalized fashion.

The story that I shared about the patient who brings her daughter to clinic visits illustrates this. Patients become part of the family here. When she and her daughter come in, you can see that the entire team that treated her is happy to see her. We take that extra step of integrating the entire team in the patients care. We are responsive and available to patients, and we take great pride in making sure that the patients queries are answered in a timely fashion. While people can receive the same treatment anywhere, its this team approach with personal involvement that sets us apart.

Visit link:
Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health

Pioneering concierge medicine management company Specialdocs and physician clients to offer compelling perspectives at the Concierge Medicine Forum October 20th 22nd

CHICAGO, Oct. 13, 2022 /PRNewswire/ -- Terry Bauer, CEO of Specialdocs Consultants, a 20-year pioneer in concierge medicine transitions and management, and several of the company's affiliated physicians will offer insights on the extraordinary growth of this dynamic and enticing practice model at the upcoming Concierge Medicine Forum (CMF) in Atlanta. Reflecting the surging demand for personalized care, the industry's signature event is on track in 2022 to be the most well-attended conference to date, according to organizers.

"What we're seeing is a genuine recognition of the pillar stone of concierge medicine - the tremendous value of a long-term physician-patient relationship," says Bauer. "The impact of the pandemic made that crystal clear and has inspired thousands of people to thoughtfully reconsider how they chose to deliver and receive care." He cited a doubling in the number of physicians converting to the Specialdocs concierge medicine model in the last few years, as well as a 10% average annual industry growth rate of the U.S. concierge medicine market over the next 8 years, as forecast by Grand View Research.

Bauer will lead key sessions covering qualities necessary for success as a concierge physician, and how to communicate the enhanced level of care to concierge patients inside and outside the exam room. He'll also discuss the expanding plethora of paths to becoming a concierge physician. "The options go well beyond traditional conversions from fee-for-service models to acquiring a practice from a retiring physician, transitioning from hospital employment or within a group practice, or joining a successful local concierge practice," he said.

In addition, Specialdocs-affiliated physicians will be featured at the conference, sharing expert perspectives that include:

"Sharing our passion for concierge medicine at CMF with insightful, long-time collaborators like Specialdocs and others is a privilege we look forward to each year," Michael Tetreault, CMF organizer and editor of Concierge Medicine Today."We're all thrilled to see the soaring interest in membership medicine practices which continue to bring balance to physicians' lives and elevate the care offered to the patients and communities they serve."

A pioneer in concierge medicine since 2002, Specialdocs is celebrating two decades of transforming physicians' professional lives, empowering them to deliver exceptionally personalized patient care.

CONTACT:[emailprotected]

SOURCE Specialdocs Consultants

Go here to read the rest:
Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire

MADRID Because of the hormone changes that occur throughout their lives, women experience sleep problems that differ significantly from those experienced by men. Indeed, 75% to 84% of pregnant women don't sleep well during the third trimester, and up to 80% of women in menopause have symptoms that prevent them from getting a good night's rest. For those seeking to a precision medicine approach, the challenge is to identify the relationship between the different sex-related phenotypes and the sleep conditions.

Irene Cano, MD, PhD, is the coordinator of the sleep department at the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). She spoke with Medscape Spanish Edition about the significant impact of hormones on sleep disorders in women.

"Reproductive hormones like estrogen and progesterone play a meaningful role in brain functions not only those linked to the regulation of reproduction but also other physiological processes related to the regulation of circadian rhythms, cognitive performance, mood, and sleep. In addition, other hormones for example, prolactin, growth hormone, cortisol, and melatonin have sex-dependent effects on sleep," Cano said.

Girls start puberty at a younger age than boys. As girls enter adolescence, they go to bed later and waking up earlier. So, girls are getting less than the 10 hours of sleep that they should be getting at this stage of life. The result is sleep debt, which gives rise to various problems: poor academic performance, attention-deficit/hyperactivity disorder, obesity, and metabolic problems, to name a few. As Ariadna Farr, RN, a sleep unit nurse, noted at SEPAR's Joint Winter Meeting, "Schools would have to start morning classes later to get adolescents to perform well academically. As the situation is now, half of the kids are falling asleep at their desks."

Cano explained the issue as follows: "In adolescence, along with changes in young women's hormone levels, we begin to see differences between the sexes. The changes in levels of estrogens and progesterone are what's responsible for the changes that, to some extent, cause those disturbances in the quality of our sleep and in the stages of our sleep."

Thus, sleep can be affected by the changes in hormone level that occur during a menstrual cycle. Estrogens, which increase during the follicular phase, are associated with rapid eye movement (REM) sleep, while progesterone, which increases during the luteal phase, increases non-REM sleep. "In the 3 to 6 days prior to menstruation, it's quite common for a woman to report difficulties falling asleep and staying asleep, in connection with a decline in the percentage of time she spends in REM sleep, in the context of premenstrual syndrome. In addition," Cano pointed out, "menstrual bleeding, that loss of blood, is associated with a drop in iron levels, making it more likely that the woman will experience restless legs syndrome."

Medscape Spanish Edition also spoke with Milagros Merino, MD, PhD, president of the Spanish Sleep Society. "The consequences that lack of sleep have on the cardiovascular system we're essentially talking about certain arrhythmias, high blood pressure, thrombosis in some cases, stroke, and heart attack. Lack of sleep also gives rise to endocrine and metabolic issues, like overweight and being at a greater risk of developing diabetes. And as for mental health, we see, among other things, attention and memory problems, emotional lability, and irascibility. Numerous studies have confirmed all of this."

Sleep apnea also deserves mention, Merino added. "Although this disorder is more common in men, we're seeing it more and more now in women, along with the cardiovascular issues that it brings about."

Another cardiovascular risk factor is insomnia, said Merino. "This sleep disorder is more prevalent in women. As hormones constantly change, the ways women sleep constantly change, from one stage of life to the next. They sleep one way in childhood, another way in adolescence, and yet another way in menopause."

During pregnancy, hormone changes are much more pronounced. During the first trimester, progesterone levels increase, making the woman drowsy. On top of that, her sleep is interrupted by more frequent visits to the bathroom as well as greater general discomfort.

In the second trimester, sleep interruptions persist but are not as bad as they were during the first 3 months. In the third trimester, 75% to 84% of pregnant women find it difficult to sleep because of aches and pains, the need to urinate during the night, cramps, and heartburn.

"Major physical changes are happening. When the bladder gets compressed, the woman has to get up and go to the bathroom. There's an interruption in her sleep," Farr explained. In addition, as the pregnancy progresses, the woman gains weight and her body mass index (BMI) increases, which can bring on obstructive sleep apnea, high blood pressure, preeclampsia, and diabetes, if not closely monitored.

Other factors include concomitant treatments, such as contraceptives, and the stages of life, such as pregnancy and lactation. "When a woman of childbearing age has restless legs syndrome, more often than not, this means that she has an iron deficiency that needs to be treated with oral iron supplements," said Merino. "However, there are few medications that can be given to a pregnant woman and RLS is relatively common during pregnancy. So, we have to turn to oral or intravenous iron supplements. Yet another matter is narcolepsy. In these cases, all medications have to be stopped during pregnancy and lactation, as they can be harmful to the baby."

While 1 in 5 menopausal women are asymptomatic, the others experience mild to severe symptoms of apnea that frequently interrupt their sleep. In this stage of life, which begins around age 50 years, the hormones that had provided protection against sleep disruptions start to decrease. As a result, there is a rise in sleep problems, especially insomnia, breathing-related sleep disorders (eg, apnea), and restless legs syndrome.

The prevalence of breathing-related sleep disorders during menopause is attributable to weight gain, the drop in levels of estrogens, and the redistribution of adipose tissue in the body. Other factors also increase a woman's risk of experiencing apnea. They range from stress, depression, and other psychological and psychiatric conditions to health status, medication use, and simply the fact of getting older. "Sleep apnea is more common in men than in premenopausal women. The numbers even out, though, when we compare men against menopausal women," Cano noted.

In women, symptoms of sleep apnea are frequently attributed to menopause. There is some overlap: insomnia, headache, irritability, low mood, decreased libido, fatigue during the day, and feeling sleepy. Only much later is the woman's condition correctly diagnosed as sleep apnea. So, even though presenting with the same complaints, a man will be diagnosed with sleep apnea sooner than a woman will in some cases, around 10 years sooner.

"On the other hand, we'd always thought that, in menopause, insomnia was characterized by awakenings occurring throughout the second half of the night. But perhaps what happens more often is that women are regularly waking up repeatedly over the course of the entire night, as opposed to experiencing a wakefulness that starts early and lasts throughout the night or having a problem falling asleep to begin with," said Merino. "The good news is that hormone replacement therapy can get things back to the way they were. And getting better sleep will help to overcome insomnia."

Insomnia is the most common sleep disorder. It affects 10% to 20% of people, mostly women. "The fact that sleep problems are more prevalent in women can be explained by the fact that among women, there is a higher incidence of conditions that disrupt sleep, such as depression," said Cano.

"Insomnia is much more common in adult women than adult men. And at menopause, women find that the insomnia only gets worse," Merino added. "But around that same age, 50 years old, what we start to see more frequently in men is REM sleep behavior disorder, a type of parasomnia that's a risk marker of degenerative nerve diseases."

Cano emphasized one finding that, though basic, is not well known. "After adjusting for socioeconomic characteristics, the difference between the sexes in reporting sleep problems is cut in half. This suggests that an important factor that explains why there are differences in sleep problems between the sexes is that women's socioeconomic status is generally lower than men's.

"As for sleep apnea in particular," Cano continued, "the kinds of symptoms that women have can be different from the classic ones seen in men snoring, pauses in breathing, and daytime sleepiness; women are being underdiagnosed, and when they are diagnosed, that's happening at a later age and at a higher BMI."

So, it's alarming that, as reported by SEPAR, 90% of women with obstructive sleep apnea are not being diagnosed.

"The majority of research studies on sleep apnea have focused on men given the prevalence of cases and the results have been extrapolated to women. This is why there's still a lot of work to be done in terms of better defining the characteristics specific to each sleep disorder and how they relate to each sex," said Cano. "Being able to identify the relationship between the different sex-related phenotypes and each condition will allow us to take a precision medicine approach tailored to a patient's particular characteristics."

As Merino put it, "The approach to sleep disorders is always personalized. The patient's sex, in and of itself, doesn't have that great of an impact on this approach. What does have a great impact are women's life stages. There are some subtle differences here and there, such as types of continuous positive airway pressure machines. The ones that are designed for women have masks that are better suited to their facial features, which differ from men's."

A precision medicine approach can be taken to treat any sleep disorder. For insomnia, the approach allows healthcare professionals to employ an appropriate cognitive-behavioral therapy plan or to determine which drugs would be more effective all on the basis of symptoms and the characteristics of the particular case. Regarding sleep apnea, Cano explained, "Taking into account the different anatomical characteristics or the higher prevalence of positional apnea will also allow us to offer different therapeutic alternatives to continuous positive airway pressure, such as mandibular advancement devices or positional therapy devices."

Women should be encouraged to develop good sleep habits. These include taking circadian rhythms into account and aligning lifestyles accordingly. It also means going to bed earlier than the men in the household. For menopausal women, recommended sleep habits range from keeping their bedroom at an ideal temperature, following a diet rich in vegetables to avoid becoming overweight, and exercising daily. While this advice may be more applicable to teenagers, adults can benefit from it as well: electronic devices should be turned off well before bedtime. Whether from a phone screen, a tablet screen, or a TV screen, the light emitted can keep one awake, which can be harmful to one's health.

Cano and Merino have disclosed no relevant financial relationships.

This article was translated from the Medscape Spanish edition.

Follow this link:
Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape

Biologic medications that neutralize IgE antibodies have long been considered a promising food allergy treatment. Now, one such medication omalizumab (or Xolair) looks likely to become the first anti-IgE biologic drug contender to treat multiple food allergies.

Researchers from the Consortium of Food Allergy Research are studying omalizumab in two ways for child and adult patients. The first is as a standalone treatment to protect against reacting to accidental exposures in those with allergies to peanut plus two or more other foods: milk, egg, wheat, cashew, hazelnut or walnut.

The second method is as an add-on treatment for oral immunotherapy (OIT) to reduce adverse reactions and improve safety.

If this drug works, its very likely to work for exposures to at least small amounts of any foods, where people could eat out without having to worry, says Dr. Robert Wood. Hes the trials principal investigator and director of pediatric allergy and immunology at Johns Hopkins Medicine in Baltimore.

Its quite possible omalizumab could help people safely eat more than small amounts of their allergens perhaps even introducing these foods into their diets.

The first 60 participants have completed stage 1 of the double-blind, placebo-controlled study. At this stage, neither researchers nor patients know who is receiving the injectable medication and who is getting the sham shot.

The initial patients then moved to an open-label extension of the trial. Everyone, including those who had received the placebo injections, got a series of omalizumab injections. After six months of shots every two to four weeks, these patients underwent food challenges. Depending on how much they could consume of the allergens without reacting, patients could either immediately start introducing those foods into their diet, or start multi-allergen OIT.

What we can say, even though the results are not fully analyzed, is that most of the participants were able to successfully introduce the foods they were allergic to into their diet, Wood says.

Those who were able to eat a lot of the food at their food challenge without reacting are given a minimum and a maximum amount of the allergenic foods to eat daily. This is to maintain their desensitization. Those who reacted to smaller amounts of the food are offered OIT, since it starts at a lower dose of the food protein.

Stage 1 of the trial is still enrolling, with a goal of getting to 225 patients. If things look good, this treatment could move out to the public in 2024 or possibly 2025, Wood says.

Omalizumab is a monoclonal, or lab-made, antibody. Its currently approved in the U.S. to treat moderate to severe asthma, nasal polyps and chronic hives. The drug, developed by Genentech and Novartis Pharmaceuticals, works by binding to IgE antibodies circulating in the blood. This prevents the IgE from binding to receptors on the surface of mast cells and basophils. Those immune system cells are involved in setting off allergic reactions and anaphylaxis.

In 2018, the U.S. Food and Drug Administration granted omalizumab breakthrough therapy designation for its potential as a food allergy treatment. Wood and his colleagues launched the OUtMATCH study the following year.

Omalizumab, and anti-IgE medications like it, have long been eyed as a food allergy treatment. The first study to look at treating peanut allergy with monoclonal antibodies was published in 2003.

Back then, researchers gave 84 peanut-allergic patients either an injection of an anti-IgE drug similar to omalizumab, called TNX-901, or a placebo. They found that after a single dose of TNX-901, participants who had initially reacted to the equivalent of half to one peanut could consume almost nine peanuts before starting to react. TNX-901, however, was never developed for commercial use by the drug makers.

Even so, anti-IgE biologic drug research continued. As well as studying biologics as standalone treatments (called monotherapy) for food allergy, researchers also wanted to know if combining a biologic with OIT could cut down adverse side effects.

During OIT, allergic individuals eat gradually increasing amounts of their allergen over several months. The goal is to increase protection in case an allergen is accidentally consumed. While OIT has a strong success rate, many patients experience adverse effects. Common symptoms are mouth and throat itching, stomach pain or vomiting. A minority of patients experience anaphylaxis.

We and many others had been pushing to move this forward, says Wood. One idea was using Xolair as a drug to treat food allergy. The second idea that has been studied is to use Xolair along with OIT as a way to make OIT safer.

The two approaches are going to look quite different, with one being a longer-term use of Xolair to increase the threshold of reactivity. While the other is a relatively short-term use of Xolair to get the dosing escalation done.

Indeed, some allergists already prescribe omalizumab off-label in conjunction with OIT. Others will wait for FDA approval of such a protocol. Wood says FDA approval is also needed for insurance coverage.

The OUtMATCH trial was about 80 percent enrolled, as of October 2022. At the start of the study, all participants do oral challenges to confirm their food allergies.

From there, one group receives injections of omalizumab every two to four weeks, while the other group receives placebo shots. After four months, a second round of food challenges determines how much of each allergen patients can tolerate.

We do think people can become protected to large amounts of food pretty quickly 20-plus peanuts. That is what we are hoping to see, says Dr. Edwin Kim, a study investigator and an associate professor of allergy and immunology at the University of North Carolina at Chapel Hill.

Additional stages are underway. Stage 2 looks at using Xolair with OIT. All Stage 2 participants receive omalizumab injections for the first eight weeks of treatment, then start either multi-allergen OIT or placebo OIT.

Then as oral immunotherapy begins, they receive the shots for the first eight weeks of treatment. After that,half the participantscontinue with multi-allergen OIT while receiving placebo shots.Theother group continues with placebo OIT, but receives realXolairinjections.All participants then go onto maintenance therapy in their respective groups to complete one year of treatment.

Stage 3 will be a real-world follow up of patients to see how they fare over the long-term having introduced the foods into their diet.

We are all very excited about this. Scientifically, its supposed to work. Hopefully we are correct, and it does work, Kim says.

If Xolair is approved as a standalone treatment, the label would say the medication is for the prevention of reactions to small, accidental exposures to food, Wood says. Patients would still be advised to avoid their allergen. (Although they could potentially do a food challenge to see if they could tolerate more, he adds).

The dosing amounts and intervals in the trial are the same as the dosing of omalizumab when its used to treat other conditions. In patients 12 and older, omalizumab can be self-injected at home after several in-office injections. Researchers say they expect food allergy patients would be able to do the same.

If injections are stopped, Xolairs effects will gradually wear off over several months. While omalizumab is usually considered very safe, it can have a range of side effects. These include rare but severe allergic reactions. The medication carries a black box warning about potentially life-threatening anaphylaxis.

Even with those caveats, Kim predicts the medication as a monotherapy would be a welcome option for many food allergy families, including those who choose not to pursue OIT.

OIT can be challenging for some families to manage. Parents work schedules and intense after-school sports schedules may make daily dosing and rest periods difficult. Many allergists arent set up to offer OIT, so accessibility is an issue in some areas.

An Olympic-level swimmer who is training constantly maybe cant do an OIT, but they can do a once a month shot, Kim says. Omalizumab might provide added protection for teenager about to leave home for college. Or, an adult might choose the shots to feel safer when dining out and traveling.

To date, there is only one FDA-approved food allergy therapy Palforzia, the oral immunotherapy for peanut allergy. While some allergists offer OIT for other foods, patients with many food allergies find it time-consuming to become desensitized to all of them.

One of the most exciting things about a drug to treat food allergy as opposed to OIT is that a drug like Xolair would not be food-specific, Wood says. If someone had food allergies other than peanuts, or peanut plus eight other food allergies, instead of having to wait for an OIT product to be available, this would be a way to cover everyones food allergies equally.

Kim says not to overlook that omalizumab as an adjunct to OIT is also exciting. If the medication can prevent adverse reactions during OIT, it could improve dropout rates during the dose escalation period. Or, it could help those worried about reactions to feel safer in trying it.

Kim envisions that one day soon food allergy families will have choices about what treatment route is best for them. This is about creating options for people. Until we have that one-shot cure, its going to be about personalized medicine. Food allergies affect people in different ways, he says.

Related Reading: Allergists See Palforzia as Start of Era of Food Allergy TherapiesOIT Study See Maturing of Immune System Over TimeNew Peanut Allergy Test Reveals if Trace Amounts Risky or Not

Read this article:
Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living

Youre one of a kind. Its not just your eyes, smile, and personality. Your health, risk for disease, and the ways you respond to medicines are also unique. Medicines that work well for some people may not help you at all. They might even cause problems. Wouldnt it be nice if treatments and preventive care could be designed just for you?

The careful matching of your biology to your medical care is known as personalized medicine. Its already being used by healthcare providers nationwide.

The story of personalized medicine begins with the unique set of genes you inherited from your parents. Genes are stretches of DNA that serve as a sort of instruction manual telling your body how to make the proteins and perform the other tasks that your body needs. These genetic instructions are written in varying patterns of only 4 different chemical letters, or bases.

The same genes often differ slightly between people. Bases may be switched, missing, or added here and there. Most of these variations have no effect on your health. But some can create unusual proteins that might boost your risk for certain diseases. Some variants can affect how well a medicine works in your body. Or they might cause the medicine to have different side effects in you than in someone else.

The study of how genes affect the way medicines work in your body is called pharmacogenomics.

If doctors know your genes, they can predict drug response and incorporate this information into the medical decisions they make, says Dr. Rochelle Long, a pharmacogenomics expert at NIH.

Its becoming more common for doctors to test for gene variants before prescribing certain drugs. For example, children with leukemia might get theTPMTgene test to help doctors choose the right dosage of medicine to prevent toxic side effects. Some HIV-infected patients are severely allergic to treatment drugs, and genetic tests can help identify who can safely take the medicines.

By screening to know who shouldnt get certain drugs, we can prevent life-threatening side effects, Long says.

Pharmacogenomics is also being used for cancer treatment. Some breast cancer drugs only work in women with particular genetic variations. If testing shows patients with advanced melanoma (skin cancer) have certain variants, two new approved drugs can treat them.

Even one of the oldest and most common drugs, aspirin, can have varying effects based on your genes. Millions of people take a daily aspirin to lower their risk for heart attack and stroke. Aspirin helps by preventing blood clots that could clog arteries. But aspirin doesnt reduce heart disease risk in everyone.

NIH-funded researchers recently identified a set of genes with unique activity patterns that can help assess whether someone will benefit from taking aspirin for heart health. Scientists are now working to develop a standardized test for use in daily practice. If doctors can tell that aspirin wont work in certain patients, they can try different treatments.

One NIH-funded research team studied a different clot-fighting drug known as clopidogrel (Plavix). Its often prescribed for people at risk of heart attack or stroke. Led by Dr. Alan Shuldiner at the University of Maryland School of Medicine, the team examined people in an Amish community. Isolated communities like this have less genetic diversity than the general population, which can make it easier to study the effects of genes. But as in the general population, some Amish people have risk factors, such as eating a high-fat diet, that raise their risk for heart disease.

Many of the Amish people studied had a particular gene variant that made them less responsive to clopidogrel, the scientists found. Further research revealed that up to one-third of the general population may have similar variations in this gene, meaning they too probably need a different medicine to reduce heart disease risks.

The findings prompted the U.S. Food and Drug Administration (FDA) to change the label for this common drug to alert doctors that it may not be appropriate for patients who have certain gene variations. Two alternative drugs have since been developed. If people have these gene variants, they know they have options, says Shuldiner. This is a great example of how study results made it onto a drug label and are beginning to be implemented into patient care.

Getting a genetic test usually isnt difficult. Doctors generally take a sample of body fluid or tissue, such as blood, saliva, or skin, and send it to a lab. Most genetic tests used today analyze just one or a few genes, often to help diagnose disease. Newborns, for example, are routinely screened for several genetic disorders by taking a few drops of blood from their heels. When life-threatening conditions are caught early, infants can be treated right away to prevent problems.

The decision about whether to get a particular genetic test can be complicated. Genetic tests are now available for about 2,500 diseases, and that number keeps growing. Your doctor might advise you to get tested for specific genetic diseases if they tend to run in your family or if you have certain symptoms.

While there are many genetic tests, they vary as to how well they predict risk, says Dr. Lawrence Brody, a genetic testing expert at NIH.

For some diseases, such as sickle cell anemia or cystic fibrosis, inheriting 2 copies of abnormal genes means a person will get that disease. But for other diseases and conditions, the picture is more complex. For Type 2 diabetes, testing positive for some specific gene variants may help predict risk, but no better than other factorssuch as obesity, high blood pressure, and having a close relative with the disease.

The latest approach to personalized medicine is to get your wholegenomesequenced. Thats still expensive, but the cost has dropped dramatically over the past decade and will likely continue to fall. Since your genome essentially stays the same over time, this information might one day become part of your medical record, so doctors could consult it as needed.

You can start to get a sense of your genetic risks by putting together your familys health history. A free online tool calledMy Family Health Portraitfrom the U.S. Surgeon General can help you and your doctor spot early warning signs of conditions that run in your family.

But personalized medicine isnt just about genes. You can learn a lot about your health risks by taking a close look at your current health and habits. Smoking, a poor diet, and lack of exercise can raise your risks for life-threatening health problems, such as heart disease and cancer. Talk to your healthcare provider about the steps you can take to understand and reduce your unique health risks.

Matching Treatments to Your Genes was originally published by the National Institutes of Health.

Follow

A part of the U.S. Department of Health and Human Services, NIH is the largest biomedical research agency in the world.

Read this article:
Matching Treatments to Your Genes - The Epoch Times

DUBLIN, Oct. 13, 2022 /PRNewswire/ -- The "Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In Vivo, In Vitro), by Application, by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.30%

Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive market growth in the forecast period.

The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.

In addition, several government entities are fueling clinical research activities and expanding the scope of applications for mAb therapies. For instance, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for the reduction of asthma attacks and the improvement of lung functionality in children.

Similarly, in March 2021, the U.S. Department of Health and Human Services invested USD 150 million in increasing patient access to monoclonal antibody therapeutics for COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen growth prospects.

Furthermore, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. Demand for such recombinant antibodies is driven by increasing commercial prospects and quality requirements that may not be fulfilled by hybridoma technologies. Hence, with the increasing commercial viability of recombinant technologies, the market is expected to witness significant growth.

Story continues

The COVID-19 pandemic has created several market expansion opportunities by fueling the development of several mAbs directed against the SARS-CoV-2 virus.

As mAbs represent a promising alternative for mitigation of the disease due to their safety and effectiveness, several mAbs such as Eli Lilly's bebtelovimab, and GlaxoSmithKline & Vir Biotechnology's sotrovimab have attained emergency use authorizations from the U.S. FDA. Such authorizations are likely to broaden the horizons for the growth of mAbs applications and propel market growth.

Monoclonal Antibodies Market Report Highlights

By source type, the human mAbs segment held the largest share of 54.07% in 2021 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies

In vitro production type held a dominating share of 78.45% in 2021 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities

The oncology segment dominated the market in 2021 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies

Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics

North America accounted for 46.2% of the market value in 2021 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others

The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary2.1 Market Outlook2.2 Market Summary

Chapter 3 Monoclonal Antibodies Market Variables, Trends & Scope3.1 Market Trends & Outlook3.2 Market Segmentation & Scope3.3 Market Driver Analysis3.3.1 Increasing Incidences Of Chronic Diseases3.3.2 Technological Advancements3.3.3 Growing Awareness Levels3.4 Market Restraint Analysis3.4.1 High Cost Of Therapeutic Mabs3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)3.6 Porter's Five Forces Analysis3.7 COVID-19 Impact Analysis3.8 Penetration & Growth Prospect Mapping

Chapter 4 Monoclonal Antibodies Market - Segment Analysis, by Source Type, 2018 - 2030 (USD Billion)4.1 Monoclonal Antibodies Market: Source Type Movement Analysis4.2 Murine4.2.1 Murine Market Estimates And Forecast, 2018 - 2030 (USD Billion)4.3 Chimeric4.4 Humanized4.5 Human

Chapter 5 Monoclonal Antibodies Market - Segment Analysis, By Production Type, 2018 - 2030 (USD Billion)5.1 Monoclonal Antibodies Market: Production Type Movement Analysis5.2 In Vivo5.2.1 In Vivo Market Estimates And Forecast, 2018 - 2030 (USD Billion)5.3 In Vitro

Chapter 6 Monoclonal Antibodies Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)6.1 Monoclonal Antibodies Market: Application Movement Analysis6.2 Oncology6.2.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Billion)6.3 Autoimmune Diseases6.4 Infectious Diseases6.5 Neurological Diseases

Chapter 7 Monoclonal Antibodies Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Billion)7.1 Monoclonal Antibodies Market: End-Use Movement Analysis7.2 Hospitals7.2.1 Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Billion)7.3 Specialty Centers

Chapter 8 Monoclonal Antibodies Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)8.1 Monoclonal Antibodies Market: Regional Movement Analysis

Chapter 9 Competitive Analysis

Abbott Laboratories

Amgen Inc.

Astrazeneca plc

Bayer AG

Biogen Inc.

Bristol Myers Squibb

Daiichi Sankyo Company, Limited

Eli Lilly and Company

F. Hoffman-La Roche Ltd.

GlaxoSmithKline plc

Johnson & Johnson Services, Inc.

Merck & Co. Inc.

Merck Kgaa

Novartis AG

Novo Nordisk A/S

Pfizer Inc

Sanofi S.A.

Thermo Fisher Scientific, Inc.

Viatris Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1y2bed

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-monoclonal-antibodies-mabs-markets-2018-2021--2022-2030---increasing-rd-activities-aimed-at-the-development-of-novel-therapeutic-mabs-301648431.html

SOURCE Research and Markets

View post:
Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -...

SAN FRANCISCO & DUBLIN--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, today announced a collaboration to improve manufacturing and analytic procedures used to develop personalized cell and gene therapies for cancer patients. Through this alliance, aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbios core next-generation manufacturing and analytical AVATAR AI technology for use in precision cancer treatment.

We are looking forward to working with the Xcellbio team and to utilizing the well-established AVATAR platform to further power our TaaS platform to deliver and deploy precision medicine proximal to patients, said Gary McAuslan, CEO and co-founder of aCGT Vector. We believe our joint efforts will further accelerate the creation of automated, end-to-end cell therapy manufacturing and QC release platforms to streamline processing and optimize patient outcomes.

aCGT Vectors enclosed, GMP-compliant manufacturing environment will demonstrate the use of Xcellbios AVATAR AI to support development and deployment of cell therapeutic procedures proximal to patients in the treatment of cancers. Through mimicking the tumor microenvironment (TME) ex vivo, AVATAR AI delivers unique capabilities to support the development of therapeutic products with improved potency and persistence as well as reduced cell exhaustion. Proprietary technology enables tight control and modulation of atmospheric pressures and oxygen concentrations in direct contact with the cell therapy product.

The AVATAR AI leverages the tight environmental control of the proven AVATAR product family, and pairs it with a specialized reader to enable real-time, label-free cell killing analysis of cell therapies targeting solid tumors. Focused on establishing next-gen immunotherapy testing workflows, the AVATAR AI system is currently in late-stage beta.

With the tremendous promise of cell therapies and the current challenges in treating patients with solid tumors, there is more interest in both designing manufacturing conditions to optimize potency, persistence, and quality and in characterizing cell potency as a critical attribute in cell therapy manufacturing, said Brian Feth, co-founder and CEO at Xcellbio. We are pleased to partner with aCGT Vector and to pair their manufacturing expertise with our unique approach to measuring and improving therapeutic potency. Together, our objective is to advance the development and deployment of cell therapies, such as CAR-T and tumor-infiltrating lymphocyte technologies, to treat solid tumors. We look forward to supporting aCGT and their initiatives, including the next-generation cell therapies for the cancer-focused HEALED Consortium.

For more information about Xcellbios AVATAR AI system or its Beta program, please visit http://www.xcellbio.com/avatar-ai.

About aCGT Vector

aCGT Vector have assembled a world class team of cell therapy and processing expertise within major cellular therapy centers of excellence. aCGT is establishing a state-of-the-art, closed-system cellular processing standardization technology and digitization loopback platform within a network of GMP ATMP PODS located proximal to rare disease patients. aCGT Vector will deliver cellular therapy processing and procedures through co-locating multidisciplinary expertise more efficiently, effectively, and safely within centers of excellence. The result will be to place less burden on patients and less stress on their cells. Digitization will permit enhanced control of cell processing and monitoring patient outcomes, thus providing value enhancement for key stakeholders, including care providers and payors. For more information, please visit https://www.acgtvector.com/.

About Xcell Biosciences

Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The companys commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform. Based in San Francisco, Xcellbio can also be found online at http://www.xcellbio.com.

Read the original post:
Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire

TUCSON, Ariz., Oct. 13, 2022 /PRNewswire/ -- Learn Look Locate (LLL) announced a partnership with Myriad Genetics, a leader in genetic testing and precision medicine, to advance awareness about hereditary breast cancer and risk assessment. As part of the partnership, Myriad will share educational information for breast cancer patients and survivors on LLL's doctor monitored and curated platform.

"We are partnering with Learn Look Locate to help further educate patients and healthcare providers about hereditary cancer testing," said Thomas Slavin, M.D., chief medical officer, Myriad Genetics. "This testing provides vital data-driven genetic insights and personalized medical information to help people with a personal or family history of cancer understand their risk of being born with a predisposition to cancer. With this information, patients and their providers can take steps to either proactively prevent disease or, if diagnosed with cancer, personalize their treatment."

The American Society of Breast Surgeons (ASBrS) recommends testing of all patients diagnosed with breast cancer. Patients without a breast cancer diagnosis, but have a family history of the disease, should discuss testing with their physicians. Genetic testing can provide an assessment of a patient's risk of developing breast cancer and provide data-driven medical information for use in personalizing medical management plans.

Myriad's MyRiskHereditary Cancer Test offers multi-gene panel testing that helps determine a patient's hereditary cancer risk associated with 11 primary cancer types, including breast cancer. Patients without breast cancer may also be eligible for further personalized risk stratification with RiskScore, a risk assessment tool that delivers a personalized five-year and remaining lifetime risk of breast cancer

"Genetic testing is one of the most powerful pieces of knowledge about yourself," said Allison DiPasquale, M.D., Breast Surgical Oncologist at Texas Oncology. "It can help predict your risk of certain cancers, help guide systemic therapy and surgical recommendations, as well as provide potential lifesaving information for relatives. Learning how to tap into the insights of your genes empowers both patients and family members. I am so honored to be part of LLL and partner with Myriad on the LLL webpage."

To learn more about hereditary cancer testing, visit LLL online. And stay up to date on the latest therapies and breast cancer news by following LLL on social media @learnlooklocate Facebook, Instagram, Twitter, LinkedIn.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World's Most Innovative Companies for 2022. For more information, visit http://www.myriad.com.

About Learn Look Locate (LLL)

Founded in 2019 by breast cancer survivor, Cynthia Jordan, LLL represents a global movement for breast cancer support and education. As part of her guiding mission to diagnose breast cancer early and educate people, LLL provides answers to the most important questions patients have: What do I need to know? Who are my resources? Where do I turn now?

LLL focuses on early detection and early diagnosis, aggregating the latest technology and research, the most cutting-edge breast cancer treatments, and information from globally recognized doctors/specialists. Understanding breast cancer at the earliest possible point of a patient's journey is critical. LLL empowers everyone touched by this diagnosis with a supportive community who share their breast cancer stories all ages, genders, and at all stages of the disease.

Join the global movement and become part of the conversation at: http://www.LearnLookLocate.com.

Media Contact:Cynthia Jordan1-407-592-4474[emailprotected]

SOURCE Learn Look Locate

View post:
Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire

INCHEON AIRPORT, SEOUL, SOUTH KOREA - 2018/06/12: A young girl communicating with a robot that is on ... [+] display at Incheon International Airport in Seoul / South Korea. The Guide Robot recognises languages; In addition to English, it can also answer Korean, Chinese and Japanese and recognise boarding cards that are scanned on the touch screen. In South Korea robots are playing an increasing role in society. AI boosts the economy in the countrys rapidly growing industry. Still, threats by terminators and lost employment threats linger. (Photo by Jonas Gratzer/LightRocket via Getty Images)

The world of social technology and public-private partnerships has been rapidly changing, and organizations must adapt their strategies to stay ahead of the curve. UN recently announced that the Republic of Korea is one of the top leaders in the 2022 digital government ranking of the 193 United Nations Member States, scoring the highest in the scope and quality of online services, the status of telecommunication infrastructure, and existing human capacity. LG NOVA is a perfect example of a private sector enterprise constantly innovating and looking for new ways to drive growth. LG NOVA is a subsidiary of LG Electronics, one of the world's largest electronics firms headquartered in Korea. It is on a critical mission to reinvent social impact for the future. The company has been at the forefront of innovation for over five decades, and its commitment to social responsibility and sustainability has earned it a reputation as a trusted partner for businesses and organizations around the globe. In fact, LG Energy Solutions is teaming up with Honda to build the $3.5 billion battery factory and create 2,200 jobs, with an overall investment projected to reach $4.4 billion as part of a joint venture in southern Ohio. President Joe Biden recently mentioned that the Honda-LG joint venture was "committing more than $5 billion toward electric vehicle battery manufacturing and factory retooling across the state.

To realize its vision of becoming a leading global provider of social technology solutions, LG NOVA has invested heavily in its Mission for the Future program. The program is designed to identify and invest in early-stage companies working on cutting-edge technologies with the potential to impact society positively.

ADVERTISEMENT

In Silicon Valley and globally, LG NOVA seeks to achieve a leadership position in socially impactful technology solutions. The company is focused on investing in early-stage companies that are working on cutting-edge technologies with the potential to impact society positively. Social innovation is reinventing how we live, work, and play, and LG NOVA is committed to supporting the companies leading this charge. The organization can drive growth and create value for shareholders, customers, and partners.

According to Dr. Sokwoo Rhee, Corporate SVP of Innovation at LG Electronics and Head of the North America Innovation Center at LG NOVA, The key industries that the LG NOVA program is seeking submissions from are digital health, electric mobility, and the metaverse. Digital Health is going to be huge. Healthcare is already huge, and you can see that many people are jumping into it right now. Electric mobility is also exploding with new solutions for electric vehicles and charging infrastructure. The government is putting money into the market, so it will only get bigger. While metaverse is still in its early stage of development, LG is continuing to explore how we can play a leading role in its development. Its a key part of our future, and we anticipate that at some point, we'll have an excellent idea or solution that we can make commercially viable."

Dr. Sokwoo Rhee, Corporate SVP of Innovation at LG Electronics and Head of the North America ... [+]ca Innovation Center at LG NOVA speaking at 2022 LG NOVA Innovation Festival

ADVERTISEMENT

Significant trends in healthcare and electric mobility include the convergence of physical and digital health, the rise of personalized and precision medicine, the growth of the wearables market, and the increasing demand for EV infrastructure as the market for EVs grows. In the metaverse, the initiative looks for applications that can create new value for users by providing an immersive and interactive experience. Dr.Rhee, previously an Associate Director for Cyber-Physical Systems (CPS) Innovation at the National Institute of Standards and Technology, U.S. Department of Commerce, continued to emphasize that "In my opinion, healthcare is a key part of smart communities. Now, if you have to go to a hospital, it's not exactly a smart city; it's just a hospital. But when you are doing healthcare at home, also known as digital healthcare, it broadens to become a community issue. So I believe digital health indirectly contributes to the concept of a smart city." The notion of the smart city is a significant trend to watch in the industry, as it represents the future of urban living and has the potential to create substantial value for companies that can provide solutions that make cities more efficient and livable.

Moreover, according to Joshua Di Frances, Head of Incubation and Senior Director, Healthcare Strategy & Enterprise Business Development, "I focus primarily on healthcare and digital health. Some companies are hospital- and consumer-facing, but they're all looking at the patient and trying to improve health. But I think some companies in that area, like Digbi Health, are exciting. They're looking at personalized health using DNA, genetics, and microbiome to understand better what each person needs. Personalizing medicine represents a huge area of growth. Medicine is going that way; we've seen it for several years. LG has a screen presence at hospitals and a hardware presence, but we also have a powerful consumer brand, and healthcare is moving to the home. And I think there's an opportunity when you think about connected devices, remote patient monitoring, and empowering patients to understand their health better where we could play a significant role. I think our leadership sees that, and thats why health is a big area of focus for us."

According to Maria Patterson, Director of New Ventures, LG Electronics, and LG NOVA Entrepreneur in Residence, Electric Vehicles are a priority in the near future due to their lack of emissions and ability to be powered by renewable energy sources. However, there are concerns about the potential for EVs to overload the electrical grid, as they require a significant amount of power to charge. One way to address this issue is by using AI to model people's behavior and better understand when and how they will use their EVs. This information can then be used to manage the charging of EVs in a way that does not overload the grid. Additionally, it is essential to ensure that these new technologies are accessible to everyone. Those who cannot afford EV chargers should not have to pay for infrastructure improvements that primarily benefit those who can. She states, "Using AI to model peoples behavior is very interesting because it makes us realize everything is very much interconnected, especially with electrification.

ADVERTISEMENT

Based on the above information, it is evident that LG Electronics is focusing on emerging industries to stay ahead of the curve and create value for their shareholders, such as healthcare and electric vehicles. This aligns with vital global megatrends. The need for better healthcare solutions will only increase as the world's population ages, and the move towards electric vehicles is gathering momentum to combat climate change. LG is well-positioned to capitalize on these trends and create significant value for its shareholders in the years to come.

2022 LG NOVA Innovation Festival

LG NOVA has spotlighted several attractive solutions focusing on health care and electric vehicles as part of their leading finalists for the Mission for the Future challenge.

ADVERTISEMENT

With digital health capabilities key to delivering healthcare to diverse and disparate communities, LG NOVA is working on expanding and scaling greater access to healthcare and personal health services.

Digbi Health is a digital care platform to prevent and reverse chronic metabolic, digestive, and mental health conditions using gut microbiome insight, genetics, AI, and food-as-medicine. Together LG and Digbi will work to make care globally accessible at home and the office and advance cure.

LifeNome is a B2B2C precision health platform powered by genomics and AI, offering personalized health and well-being solutions to the world's leading enterprises. LG and LifeNome plan to bring to market the world's first precision maternal and family health platform, supporting pregnant individuals 24/7 from conception to the early stages of a child's life.

ADVERTISEMENT

Mindset Medical is a sensor-based technology platform that can use a camera in patient-owned devices to capture health and biological readings to assist doctors in enhancing medical diagnosis and treatment effectiveness. Expanding upon new services available to doctors and providers, LG's work with Mindset Medical is expected to make it easier for medical providers to understand patient health over time or during live virtual doctor visits.

XRHealth develops virtual treatment rooms, integrating immersive VR/AR technology, licensed clinicians, and real-time data analytics on one platform, providing a comprehensive therapeutic care solution for patients through the continuum of care, from the hospital to the patient's home. LG and XRHealth will continue to grow the service offering to deliver more insights to clinicians and enable more precise personalized care.

The solutions in this category lead to social innovation by bringing technology-enabled solutions to healthcare's most challenging problems and making it easier for people to get the care they need. Specifically, these companies are focused on making it easier for people to access care, whether that's through at-home solutions or by providing more data to doctors to help them make better decisions.

ADVERTISEMENT

With LG's commitment to sustainability as an organization, LG NOVA is working to pursue new opportunities to expand access to electric vehicles (EV) and electric mobility solutions by enabling more businesses to leverage their infrastructure to provide EV services.

Driivz empowers major EV service providers with an end-to-end EV charging and intelligent energy management software platform. LG and Driivz will work together to enable the hospitality industry across the United States to offer EV charging-as-a-service while optimizing their EV charging operations and providing their customers with an exceptional EV charging experience.

I-EMS Solutions, Ltd. uses innovative AI and blockchain-based distributed energy resource management systems (DERMS) and transactive energy software platforms to enable power optimization across smart cities, smart homes, and e-mobility. By working with I-EMS, LG will help modernize the electricity grid and optimize energy management to deliver better power management solutions for the market.

ADVERTISEMENT

SparkCharge offers an affordable and convenient way for electric vehicle owners to charge their EVs without a direct-access charger at home or on the road. LG and SparkCharge plan to work together to deliver turnkey EV solutions for businesses to create a stream of revenue from their parking spaces.

The companies in this category focus on making it easier for people to switch to electric vehicles and expanding the infrastructure necessary to support widespread adoption. This is an integral part of LG's commitment to sustainability, as electric vehicles have a lower environmental impact than traditional gas-powered cars.

LG NOVA's Mission for the Future program is a testament to the pressing need for social innovation globally. The company is working with startups in various industries to create new solutions for some of the world's most pressing problems. LG NOVA is committed to positive change in the world, from healthcare to electric vehicles. Other organizations can begin to emulate this program by establishing social innovation initiatives and partnering with startups to create new technologies and services that address pressing global issues.

ADVERTISEMENT

See the original post here:
Important Mission By LG To Reinvent Society With Future Growth - Forbes

If youve ever lied about your height on a dating app, we now know to whom you can address your grievances. No, not any reinforced societal expectations about what heterosexual relationships look like or how traditional masculinity or femininity manifests, but a stretch of genetic variations.

Height is one of the easiest physical characteristics to measure, and we know that its a trait with high hereditability, meaning inherited genes almost entirely determine it. This trait seems like it should be a fairly straightforward one to parse genetically, but the actual places where gene variations occur have been hard to pin down.

Researchers in Australia, the U.K., and the U.S. published a study on Wednesday in the journal Nature that provides evidence for more than 12,000 spots in the human genome that are associated with height.

Whats new In the largest and most diverse genome-wide association study (GWAS) to date, the studys authors have identified 12,111 places in the human genome associated with height. The team analyzed existing genetic data from nearly 5.4 million people, more than a million of whom were not of European ancestry.

Throughout ones DNA are single nucleotide polymorphisms (SNP, pronounced snip), which are spots for genetic variation. SNPs are, in part, whats responsible for eye and hair color, height variation, and pretty much any other inherited trait. These arent mutations but spots where a particular nucleotide (adenine, cytosine, guanine, and thymine) exists. These nucleotides encode certain traits.

This study has pinpointed more than 12,000 locations in the human genome where those SNPs coding for height occur.

Why it matters As simple as height may seem, theres so much we still dont know about it.

Loic Yengo, lead author, and statistical geneticist at the University of Queensland, says this work sets the stage for future genetic investigation of other traits and diseases, demonstrating that genetic data alone can contribute a significant portion of trait variation and risk of disease.

It also offers a guide on sample sizes. Though this is the largest GWAS to date, it will likely impel broader and broader studies with even more people.

Widening the sample size is important for the future of personalized medicine, Yengo wrote in an email to Inverse. The more genetic material included, the better researchers will get at identifying at-risk patients before an inherited disease or trait progresses beyond prevention.

More directly, this study teaches something about the biology of bone growth and can eventually help us design treatments for certain skeletal growth disorders, Yengo wrote to Inverse.

Digging into the details Genetic information on European ancestry is now saturated. There arent many more unknown common variants associated with height in this population. According to Yengo, these more than 12,000 genetic variants account for about 40 percent of height variation in European ancestry.

Weve more or less finished mapping them, at least for European ancestry, Joel Hirschhorn, senior author, and a pediatric endocrinologist at Boston Childrens Hospital tells Inverse. Genetic rarities, however, still remain. Yengo now wants to focus on rare variants present in less than 1 percent of that population.

And, there are plenty of other ancestry groups that must be investigated for common variants. In this study, fewer than 78,000 people represented South Asian ancestry. But Hirschhorn and Yengo point to the importance of better understanding height in African ancestries.

Ancestries with an s because of the large diversity existing on the African continent, Yengo writes. Considering human life originated in Africa, information from these populations could provide novel insights.

Humans all started as one relatively small group in Africa, Hirschhorn says. Some of that genetic diversity left Africa, and some of it stayed behind. Since these genes come from much older populations, it has more genetic variability because its had so much more time to evolve.

Theres more to discover and better ability to pinpoint where the right variants are, but to do that, you need large studies of folks with African ancestry, he says.

Whats next These analyses will only get bigger and more diverse. Yengos vision for this researchs future is to home in on rarer genetic variants that alter height and to find even more height variants in other populations.

Hirschhorns interested in the immediate biological understanding we can glean. The more relevant genes we understand, the better we can get to know the biological mechanisms behind how height and skeletal growth work. He also says this study offers an opportunity for prevention and intervention when it comes to genetic disorders or diseases that affect height.

And as a pediatric endocrinologist, I see a lot of kids where the parents come in because theyre concerned about their child growing too slowly, he says. As sci-fi as it may seem, its not too hard to look at that kids genetics to see if perhaps theyre going to end up on the shorter side based on variants identified. But if that kids genetics suggest they should end up on the taller side, then there may be something else going on worth investigating.

Nobody needs genetic testing to at least partially, if not mostly, understand their own height. If youre curious, see if you can learn your parents heights, and that should offer some insight.

LEARN SOMETHING NEW EVERY DAY.

Read more:
Scientists identify more than 12,000 spots in the human genome associated with height - Inverse

Pokagon Flag

Harper Institute collecting Native American samples to address health disparities

Dr. Gerald Morris, the medical director for the Pokagon Band of Potawatomi Indians that live in northern Indiana and southwest Michigan, isnt certain that the Native American patients he sees show higher rates of cancer than the rest of the population though he suspects it.

The one thing that stands out to me is, oftentimes, theyre more advanced when we find them, said Morris, who is a Pokagon citizen. I think they have the same issues as other patients in terms of the types of cancers. Its just that they tend to be more advanced when I do see them.

Morris said the reason the cancers are more advanced could trace back to historical access to health care, which leads to lower rates of cancer screening. He hopes that a partnership being developed between the Pokagon Band and the University of Notre Dame'sHarper Cancer Research Institute (HCRI) will help raise awareness of the importance of screening and early detection to address measurable disparities in cancer treatment outcomes involving Native Americans.

The Pokagon Bands tribal leadership plans to invest $25,000 to help fund the project. Scott Brewer, a senior vice president at the tribes Four Winds Casino Resorts, oversees the companys philanthropic activities and proposed the HCRI project to his tribal council. He said the research disparities Harper presented speak for themselves of about 90,000 cancer tissue samples in the Cancer Genome Atlas at the National Cancer Institute, only 114 came from Native Americans.

Thats .001 percent of the total, even though people identifying as at least partially American Indian or Alaska Native constitute about 3 percent of U.S. population.

Weve partnered with the University on several things, but this is the first health initiative, Brewer said. It was the easiest sell for me because its research to try to get a cure, and the research is specific to Native Americans.

The project aims to double the number of cancer tissue samples that come from Native Americans through several outreach efforts. While Harper is in the early stages of relationship building with the Pokagon Band, it has been working for a few years with other minority groups: the Kalispel tribe in eastern Washington state, and medical groups in Puebla, Mexico.

Andy Bullock, associate director of HCRI, explained why its so important to diversify the cancer tissue samples available for research. His rationale starts with the direction the future of cancer research is taking.

Cancer is not one disease, its thousands, Bullock said. It used to be cancer of the breast, colon, kidney, etc. With more personalized medicine, its now more about the type of mutation.

Cancer comes from a mutation in a persons DNA, leading cells to grow uncontrollably in different ways. Targeted cancer drugs and chemotherapy attempt to block different pathways that are turned on by these mutations in the body. But people of different race or ethnicity with the same cancer might have different mutations that activate the cancer-driving pathway.

It might be different between a Caucasian person and Native American person and African American person, said M. Sharon Stack, the Anne F. Dunne and Elizabeth Riley Director of HCRI. We don't know for most cancers in minority populations because nobodys really looked.

Most cancer tissue is collected at elite cancer centers, where there is an over-representation of white patients that can afford treatment there. Minority cancer patients are more likely to seek treatment at local, often less-costly cancer centers. These trends drive the disparity that leads to such low numbers of Native Americans in the Cancer Genome Atlas.

The current model is we come up with a drug that helps white people, then hope it helps other people too, Bullock said. We are trying to invert that model. We want to research Native Americans and see how well those pathway blockers help them and other people.

Stack said the project fits the Universitys mission of serving populations often marginalized in the past, but its also a really compelling scientific question.

A 2022 American Cancer Society report on American Indian and Native Alaskan populations found that cancer incidence in these indigenous communities is higher nationally than among whites, especially for lung, colorectal and kidney cancers. The report notes that lower levels of health insurance and chronic underfunding of the U.S. Indian Health Services exacerbates the problem.

Within the national numbers are wide variations, partly because there are 574 federally recognized tribes and more than 200 that remain unrecognized. Even when factors like health care and poor housing are equalized, wide disparities in cancer cases remain. For instance, Northern Plains Indians are four times more likely to have kidney cancer than whites. Survivability charts also show disparities, likely due to later detection.

Bullock said HCRI has been working for several years with partners in eastern Washington because an alumnus there donated money for cancer research. Ryan Gee, who graduated in 1998, is CEO of Gee Automotive companies with 35 car dealerships across several western states.

Gee, whose wife survived cancer, said the fight against the disease is his side passion. He co-founded the Community Cancer Fund with a friend who survived cancer against great odds. The organization raises money for cancer research and to help families in the Northwest cope with the severe economic impact of cancer treatment.

The Kalispel Indian tribe is a large donor to the fund, so Gee asked Harper about cancer research among Native Americans and learned it was lacking. What if we set a goal to double the amount of Native American research samples in the database through Harper at Notre Dame, Gee said.

Gees nonprofit works with the MultiCare hospital system in Washington state, which has helped Harper collect about 20 cancer tissue samples from Native Americans so far.

Native American populations experience much higher cancer rates than non-Hispanic white people in the U.S and are historically under-represented and critically under researched, said Annie Reedy, MultiCares chief research and education officer. Through this collaboration with Notre Dame we are moving toward a greater understanding of cancers in Native Americans and building a foundation for future clinical trials and treatment advances for this population.

Fundraising is an important part of this research because the cancer tissues are expensive to analyze. When a lump or tumor is removed from a patient, the doctors will perform a biopsy on a small slice to determine if its cancerous. The rest is considered medical waste.

Stack said it can be difficult to convince people to share the leftover portions with tissue banks, especially if the target population is mistrustful of the medical community. Relationship building can take years. A tissue bank must strip out identifying information that could lead back to the donor, leaving only basic demographic information.

Harper contracts with a Chicago company that extracts DNA from samples and looks for about 600 mutations linked to cancer. The $2,500 process also analyzes the RNA sequence, which is a blueprint of the DNAs genetic code that gets made into the proteins that form hair and skin and bones the different parts of the body. Mens basketball coach Mike Brey raised money for the project through his Coaches vs. Cancer work.

Another branch of this ongoing project works with partners in Puebla, Mexico. There is a huge disparity in childhood leukemia survival between people in America and Mexico. In America, more than 90 percent of leukemia patients live to the 10-year marker that signals successful treatment. In Mexico, only about 60 percent live for four years.

HCRI has been collecting samples from pediatric patients in South Bend to compare them with samples from Mexican patients.

Ideally we would have Caucasian kids and also kids of Latin American origin that happened to be raised in South Bend to see if any differences are genetic, or if it could be an environmental effect, Stack said.

Maria Cristina Miranda Vergara earned a doctoral degree in biochemistry from Notre Dame in May. As a student, she studied biomarkers that could improve early cancer detection, working with partners at the Catholic Universidad Popular Autnoma del Estado de Puebla. Now working in biochemical research in Puebla, Miranda Vergara helps process Mexican samples using the same protocols so that the data can be compared to Notre Dames research.

My dream is to develop some sort of microfluidic device that would allow us to detect cancer biomarkers in the field, so we could do early diagnosis of children in their communities, she said. Its difficult to determine the symptoms of cancer, but we need to improve early detection to get the right treatment and improve outcomes.

The common thread between the Harper projects in Mexican and Native American communities is to improve cancer survival by analyzing distinct populations that have not been studied as thoroughly in the past.

Priscilla Gatties, director of Health Services for the Pokagon Band, said Harpers research can help address disadvantages that Native American communities have developed due to a lack of historical health data. She said her mother-in-law, a Pokagon citizen, is fighting against kidney cancer using medication that didnt exist a decade ago.

From my perspective, Im very excited about what Harper is doing, Gatties said. Theres a lot of new research and information, and we can be a part of that. I think thats going to help patients and save lives, even if its later on down the road.

Read more from the original source:
The future of cancer research | News - ND Newswire

Former chairman of CareDx, Inc. and seasoned global industry executive with track record of transforming organizations will lead Kyverna and drive its growth as it aims to bring a new class of targeted gene therapies to treat severe immune-related diseases

Company plans to submit Investigational New Drug application for its lead program KYV-101, a novel CD19 CAR T-cell therapy, for the treatment of lupus nephritis

Dominic Borie, M.D., Ph.D., named president, research and development to continue advancing company's core program KYV-101 and strategic partnerships with Gilead and Intellia

Kyverna's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease

EMERYVILLE, Calif., Oct. 13, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company's chief executive officer (CEO). Dr. Maag succeeds Dominic Borie, M.D., Ph.D., who has been named Kyverna's president of research and development (R&D). Dr. Maag also joins Kyverna's board of directors.

"We are thrilled to welcome Peter as Kyverna's new CEO," said Ian Clark, chair of Kyverna's board of directors. "Peter is an accomplished executive with extensive industry experience at private and public companies spanning three continents.His consistent record of driving transformational growth in healthcare through product innovation, creative business development, sequential financings, and sound investment strategieswill be invaluable to progress Kyverna and deliver on its mission to help bring new and much-needed treatment options to patients with serious autoimmune and inflammatory diseases."

Dr. Maag has more than 20 years of executive management experience in the pharmaceutical and diagnostic industry. Most recently, he was executive chairman, president and CEO of CareDx where he had built the company from a small start-up into a public company and industry-leading powerhouse in transplantation through a series of BD&L and financing transactions. CareDx serves the transplant community with breakthrough technologies in more than 60 countries and has created a strong presence in this specialty market. Prior to joining CareDx in 2012, Peter held multiple positions in Novartis with increasing responsibilities. As President of Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Previously, he led one of Novartis' key affiliates as country president, Germany, and lived in a dynamically growing market as country president, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise.

"I am passionate about patient care and am honored to be appointed to lead Kyverna and this extraordinarily talented team. This is such an exciting time to join the company with key milestones like our submission of an IND for our lead candidate, KYV-101 in lupus nephritis tomorrow. This important regulatory milestone will provide a runway to move KYV-101 into the clinical phase and brings us a step closer to developing a new treatment option for lupus nephritis," said Dr. Maag. "I believe that Kyverna is at the forefront of revolutionizing how we treat severe immune-related and inflammatory diseases with its new class of cell therapies. With multiple shots on goal, I believe that Kyverna is well positioned to transform how autoimmune diseases are treated."

Prior to joining Novartis, Peter worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, MiroMatrix, and the Personalized Medicine Coalition. Peter studied pharmaceutical sciences in Heidelberg, London, and Berlin.

In addition to Dr. Maag's appointment, Kyverna announced that Dr. Borie will step away from his CEO role and has been named president of R&D.

"We are grateful for the significant contributions Dominic has made in bringing Kyverna out of stealth in 2020 and growing the company and building out Kyverna's core programs," added Mr. Clark. "Dominic has performed admirably, and we could not be more pleased that he will serve as president of Kyverna's R&D operations. We look forward to working closely with him and his team to continue moving forward our autologous and allogeneic programs, as well as our collaborations with Gilead and Intellia so that we can continue to strive to bring new treatments to patients rapidly."

About KYV-101KYV-101 is an autologous version of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use in B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, and inflammatory myopathies. Kyverna has obtained exclusive, worldwide licenses from the National Institutes of Health (NIH) to use this CD19 construct in both autologous and allogeneic CAR T-cell therapies.

About Kyverna TherapeuticsKyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. In addition to aiming to develop next-generationchimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic settings, Kyverna is creating synReg T cells, a synthetic version of Regulatory T cells (Tregs), powerful natural immune cells that control immune homeostasis through multiple immunosuppressive mechanisms. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. For more information, please visit https://kyvernatx.com.

SOURCE Kyverna Therapeutics

Go here to see the original:
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire

Future Market Insights Global and Consulting Pvt. Ltd.

The laboratory information systems market in Germany is set to exhibit a growth at a 9.9% CAGR during the forecast period 2022 -2030. Sales of laboratory information systems in China are forecast to increase at a 9.4% CAGR over the forecast period

NEWARK, Del, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The global laboratory information systems market is worth US$ 1.9 Bn as of now and expected to reach US$ 4.2 Bn by the year 2030 at a CAGR of 10.2% between 2022 and 2030.

Laboratory Information System (LIS) comes across as a collection of operating systems, software, and hardware used for processing, storing, and managing data in the clinical laboratories. As such, it has turned out to be one of the essential tools to support operations in the modern laboratories. They are inclusive of managing and processing data pertaining to several processes and testing.

The healthcare vertical has witnessed several technological advancements in the last few years, and laboratory information systems are no exception. The application areas include sample tracking and also as enterprise resource planning tools managing several facets of informatics. The systems actually let end-users accumulate patients data and also record it on database for managing the patients better.

Besides, quick adoption of explicit research on genomic studies and automation is catalysing utilization of laboratory information systems. With growing biobanks, notable investments in the novel technologies, easily available laboratory information systems products, services, and stern regulatory requirements across all the industries, the laboratory information systems market is all set to grow on an unstoppable note in the near future.

Request a sample @https://www.futuremarketinsights.com/reports/sample/rep-gb-875

Additionally, standardization of clinical trials coupled with modernization of regulatory pathways in the Peoples Republic of China is aiding the growth of laboratory information systems market. Cloud-based services are being rapidly adopted. High-speed internet is another factor to be attributed to.

Story continues

The ongoing trend implies tabling dedicated laboratory information systems with custom, commercial, and open source software interface with diverse budgetary specifications. Future Market Insights has etched these findings with future perspectives in its latest market study entitled Laboratory Information Systems Market.

Key Takeaways from Laboratory Information Systems Market

North America holds the largest market share due to the US being subject to quick adoption of well-structured healthcare IT sector and lab automation and the status quo is expected to remain unchanged even in the forecast period.

Europe stands second, with Germany leading from the front. It is expected to witness a CAGR of 9.9% in laboratory information systems market in the forecast period due to rising adoption of automation.

The Asia-Pacific is expected to grow at the fastest pace in the laboratory information systems market with China yielding personalized medicine with feasible support from the government.

Cloud-based laboratory information systems are dominating the market and would continue to do so even going forward.

By application, clinics hold the largest market share (over 48%).

Automation, in line with Industry 4.0, is expected to accelerate the laboratory information system (LIS) market in the forecast period, says an analyst from Future Market Insights.

Ask an Analyst@https://www.futuremarketinsights.com/ask-question/rep-gb-875

Competitive Arena

CTI, in August 2021, entered into partnership with LabWare Inc. with the objective of expanding the formers laboratory services for supporting research related to cell & gene therapy.

Oracle Corporation, in December 2021, partnered with Cerner Corporation for jointly announcing acquisition of the latter.

Orchard Software Corporation, in May 2021, completed acquisition of Corwen, LLC for expanding molecular testing capabilities and make way for integrated and comprehensive LIS solutions.

PathWest, in January 2021, integrated its SoftBank (new LIS transfusion medicine module) with NBAs (National Blood Authoritys) BloodNet LIS Interface.

CompuGroup, in December 2020, completed acquisition of Schuyler House for strengthening the footprint all across the US.

LabVantage Solutions, in July 2020, did launch its 100% integrated Scientific Data Management Systems (SDMS) via its LabVantage 8.5 edition.

Abbott, in July 2019, came up with STARLIMS Life Sciences Solution 11.1 for managing complex testing and sample workflows.

What does the Report Cover?

Future Market Insights offers an exclusive perspective and various real-time insights on the laboratory information systems market in its latest study, presenting historical demand assessment of 2016 2021 and projections for 2022 2030.

The research study is based on component (hardware, software, and services), by delivery mode (on-premise and cloud-based), and by end-user (hospitals, clinics, independent laboratories, and likewise).

Browse Full Report @ https://www.futuremarketinsights.com/reports/laboratory-information-systems-market

Key Market Segments Covered in Laboratory Information Systems Industry Research

By Components:

By Delivery Mode:

By End User:

Hospitals

Clinics

Independent Laboratories

Others

By Region:

Ask For Customization@https://www.futuremarketinsights.com/customization-available/rep-gb-875

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Analysis and Recommendations

2. Global Laboratory Information Systems Market Overview

2.1. Introduction

2.1.1. Global Laboratory Information Systems Market Definition

2.1.2. Global Laboratory Information Systems Market Taxonomy

2.2. Market Dynamics

2.2.1. Drivers

2.2.2. Restraints

2.2.3. Opportunity

2.3. Global Laboratory Information Systems Market Trends

2.4. Global Laboratory Information Systems (LIS) Market Demand (in Value in US$ Mn) Analysis 2015-2021 and Forecast, 20222030

2.5. Global Laboratory Information Systems Market Size (Value) Forecast

2.5.1. Y-o-Y Growth Projections

2.5.2. Absolute $ Opportunity

Read More TOC.

Have a Look at Related Research Reports of Healthcare

Radiology Information System RIS Market Size: The Radiology Information System market is projected to register a CAGR of 7.6% during the forecast period, up from US$ 809.8 million in 2020 to reach a valuation of US$ 1,315.6 million by 2026

Clinical Information System Market Sales: The clinical information system market is expected to record a CAGR of 8% during the forecast period, reaching a valuation of US$ 1560 Mn by 2027

Laboratory Filtration Devices Market Trends: Laboratory Filtration Devices Market - Global industry segment analysis, regional outlook, share, growth; laboratory filtration devices market forecast 2017 to 2027 by future market insights

Oncology Information Systems Market Share: The oncology information systems market is projected to be worth US$ 2.59 Bn by 2022 and is expected to grow to US$5.4 Bn by 2032, at a CAGR of 7.8% from 2022 to 2032

Clinical Decision Support Market Growth: The global clinical decision support market is likely to reach a US$ 2.2 billion valuation in 2022

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc. Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USA T: +1-845-579-5705 For Sales Enquiries: sales@futuremarketinsights.com

View original post here:
Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo...

Dublin, Oct. 11, 2022 (GLOBE NEWSWIRE) -- The "Stem Cell Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global stem cell manufacturing market size reached US$ 11.2 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 18.59 Billion by 2027, exhibiting a CAGR of 8.81% during 2021-2027.

Stem cells are undifferentiated or partially differentiated cells that make up the tissues and organs of animals and plants. They are commonly sourced from blood, bone marrow, umbilical cord, embryo, and placenta. Under the right body and laboratory conditions, stem cells can divide to form more cells, such as red blood cells (RBCs), platelets, and white blood cells, which generate specialized functions.

They are widely used for human disease modeling, drug discovery, development of cell therapies for untreatable diseases, gene therapy, and tissue engineering. Stem cells are cryopreserved to maintain their viability and minimize genetic change and are consequently used later to replace damaged organs and tissues and treat various diseases.

Stem Cell Manufacturing Market Trends:

The global market is primarily driven by the increasing venture capital (VC) investments in stem cell research due to the rising awareness about the therapeutic potency of stem cells. Apart from this, the widespread product utilization in effective disease management, personalized medicine, and genome testing applications are favoring the market growth. Additionally, the incorporation of three-dimensional (3D) printing and microfluidic technologies to reduce production time and lower cost by integrating multiple production steps into one device is providing an impetus to the market growth.

Furthermore, the increasing product utilization in the pharmaceutical industry for manufacturing hematopoietic stem cells (HSC)- and mesenchymal stem cells (MSC)-based drugs for treating tumors, leukemia, and lymphoma is acting as another growth-inducing factor.

Moreover, the increasing product application in research applications to produce new drugs that assist in improving functions and altering the progress of diseases is providing a considerable boost to the market. Other factors, including the increasing usage of the technique in tissue and organ replacement therapies, significant improvements in medical infrastructure, and the implementation of various government initiatives promoting public health, are anticipated to drive the market.

Key Players

Key Questions Answered in This Report:

Key Market Segmentation

Breakup by Product:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Stem Cell Manufacturing Market

6 Market Breakup by Product

7 Market Breakup by Application

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/5iujo7

Link:
Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga

Precision medicine, sometimes known as "personalized medicine" is an innovative approach to tailoring disease prevention and treatment based on the individuals unique characteristics and genetic make-up. Precision medicine software provides the healthcare and life sciences community with integrated data and data-driven insights to strengthen their precision medicine program.

Move from the Traditional One-Size-Fits-All Approach to Personalized Care Approach

The precision medicine approach promises better clinical outcomes, safer medicines, and less wastage/cost savings. With the increasing demand to provide value to healthcare systems, drug developers have started to move away from the traditional one-size-fits-all approach to the personalized care approach.

Favorable Government Initiatives is Driving the Precision Medicine Software Market

Realizing the long-term benefits of personalized care in improving population health and reducing healthcare costs, governments across the world are supporting advanced treatments like precision medicine through initiatives, regulatory changes, and/or funding research.

For instance, in US, The Oncology Care Model, a specialty payment and delivery model developed by the CMS Innovation Center is providing incentives that have led to a surge of large community provider networks implementing precision medicine initiatives.

Some of the other programs to advance the research/use of precision medicine include The Precision Medicine Initiative (PMI), All of Us Research Program, precision FDA, and Million Veteran Program. In addition, FDA issued seven guidance documents in 2020 related to precision medicine. All these efforts would eventually boost the demand for precision medicine software.

Upcoming Growth Opportunities in Oncology

Precision medicine holds a tremendous promise for reshaping the way cancer is treated. The growing prevalence of cancer and increasing funding for cancer research would propel the adoption of precision medicine in oncology. High-quality patient datasets are the foundation to bring precision oncology into clinical practice. Thus, providing great opportunities for precision oncology software providers.

Rising Market Challenges: Precision Medicine Software Market

For the emergence of precision medicine in every medical sector, the medical industry needs to know how to optimize the utilization of big data with the increase in the amount of genomics, health, and lifestyle information.

Further, the high costs of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the shortage of expert technicians/bioinformaticians are some of the key challenges faced by this market players.

Competitive Landscape Analysis: Precision Medicine Software Market

The global precision medicine software market is highly competitive and fragmented. Some of the leading and emerging players operating in the global precision medicine software market are Syapse, Fabric Genomics, Sophia Genetics, 2bprecise, PierianDx, PhenoTips, Foundation Medicine, GenomOncology, Translational Software, LifeOmic Health, Sunquest Information Systems, Tempus, Human Longevity and N-of-One Inc.

Explore Detailed Market Research Insights on Precision Medicine Software Market @ https://meditechinsights.com/precision-medicine-software-market/

Visit link:
Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World

Northwell Health, New York largest health care provider, and Google Cloud partner to improve patient care.

"Digital transformation is critical to our long-term goals of further advancing clinical excellence in our health system," said Michael Dowling, president and CEO, Northwell Health. "This partnership will help us deliver personalized experiences by safely and privately harnessing customers' data to enhance care, well-being, and equity in care for our patients."

As part of this partnership, Northwell Health will leverage Google Cloud as its preferred cloud platform for infrastructure modernization, and to build an interoperable data platform with AI and ML capabilities. This includes contextual recommendations that equip nurses and clinicians with decision making support that goes beyond summarizing the information from different records, building relationships between the information to help support the right actions at the right time.

"People want the same kind of seamless experiences and access to their healthcare that they have in other areas of their life, and healthcare providers need to meet these demands while also running the organization more efficiently," said Joe Miles, managing director, Global Healthcare & Life Sciences Solutions for Google Cloud. "Northwell Health is taking the lead on innovation and interoperability to transform health and wellness for millions of New Yorkers."

Privacy and security will be of the utmost importance in all aspects of this digital transformation. Through the implementation of Google Cloud's reliable infrastructure along with Northwell Health's layers of security, privacy controls and processes, the access and use of patient data will be appropriately protected.

AboutNorthwellHealth

Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 80,000 employees 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners are working to change health care for the better.We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionalsat the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and theHofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visitNorthwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

About Google Cloud

Google Cloud accelerates every organization's ability to digitally transform its business. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.

SOURCE Google Cloud

Excerpt from:
Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire

LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Companys research report on the single-cell analysis market, the growing focus on personalized medicine across the globe is contributing to the growth of the single-cell analysis market. Personalized medicine is a medical practice that uses the genetic profile of a particular individual to make decisions for the treatment of a disease and also for the prevention and diagnosis of the disease for that specific individual. The single-cell analysis could help in the treatment of various diseases by giving deep insights into the needs of individual patients, the nature of the disease, and the personalized treatment for them. Thus, more patients are opting for personalized medicine for themselves. For example, according to the survey conducted in July 2021, by Dosis, a dosing platform provider, of 1,000 people, 85% of patients think that personalized medicine will improve care for them and 80% of patients think that personalized medicine should be available for all. Hence, the increasing focus on personalized medicine is supporting the growth of the market.

Request for a sample of the global single-cell analysis market report

The global single-cell analysis market size is expected to grow from $2.58 billion in 2021 to $2.9 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The single-cell analysis industry growth is expected to reach $4.9 billion in 2026 at a CAGR of 14.1%.

Companies in the single-cell analysis market are focusing on technological advancements to deliver intact and viable single cells. With the help of technological advancements, companies in the market are maintaining sample integrity through shipping, storage, and processing, increasing the recovery rates of delicate cells and also eliminating the need for specialized instruments. For example, in October 2021, PerkinElmer, a US-based company engaged in diagnostics, food, environmental and industrial testing, and life science research, along with Honeycomb Biotechnologies, a US-based company involved in single-cell genomic analysis, launched HIVE scRNAseq solution, which is a portable, single-use, and handheld device that allows gentle capture, robust storage, and ease of processing for the analysis of single-cell samples. It has RNA-Seq libraries from a variety of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes, and neurons. The HIVE system is simple to use and offers potential for laboratories conducting fundamental, translational, clinical, and preclinical research.

Major players in the single-cell analysis market are Becton, Dickinson and Company, Merck KGAA, QIAGEN N.V., Thermo Fisher Scientific Inc., Illumina Inc., Fluidigm Corporation, 10X Genomics, Bio-Rad Laboratories, Novogene Corporation, Agilent Technologies Inc., Sartorius AG, Luminex Corporation, Fluxion Biosciences, and Oxford Nanopore Technologies.

The global single-cell analysis market analysis is segmented by product into consumables, instruments; by workflow into single-cell isolation and library preparation, downstream analysis, data analysis; by technique into flow cytometry, next generation sequencing, Polymerase Chain Reaction (PCR), microscopy, mass spectrometry, others; by application into cancer, immunology, neurology, stem cell, non-invasive prenatal diagnosis, in-vitro fertilization, others; by end-user into academic and research laboratories, biotechnology and pharmaceutical companies, hospital and diagnostic laboratories.

North America was the largest region in the single-cell analysis market in 2021. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in TBRCs single-cell analysis market outlook are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Single-Cell Analysis Global Market Report 2022 Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provide single-cell analysis market overviews, single-cell analysis market analyze and forecast market size and growth for the whole market, single-cell analysis market segments and geographies, single-cell analysis market trends, single-cell analysis market drivers, single-cell analysis market restraints, leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Not the market you are looking for? Check out some similar market intelligence reports:

Metabolomics Global Market Report 2022 By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors Of Metabolism), By Metabolomics Instruments (Separation Techniques, Detection Techniques), By Metabolomics Bioinformatics Tools & Services (Bioinformatics Tools And Database, Bioinformatics Services) Market Size, Trends, And Global Forecast 2022-2026

Cancer Tumor Profiling Global Market Report 2022 By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray), By Process Type (Genomics, Proteomics, Epigenetics, Metabolomics), By Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications) Market Size, Trends, And Global Forecast 2022-2026

Flow Cytometry Global Market Report 2022 By Type (Instruments, Reagents & Consumables, Software, Accessories, Services), By Technology (Cell-Based, Bead-Based), By End User (Hospitals And Clinics, Academia And Research Institutes, Pharmaceutical And Biotechnology Companies), By Application (Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Haematology) Market Size, Trends, And Global Forecast 2022-2026

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Link:
The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's...

Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155163 (2000).

CAS PubMed Article Google Scholar

Suzuki, K. et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand. J. Rheumatol. 32, 197204 (2003).

CAS PubMed Article Google Scholar

Mishima, S. et al. Higher PGD(2) production by synovial mast cells from rheumatoid arthritis patients compared with osteoarthritis patients via miR-199a-3p/prostaglandin synthetase 2 axis. Sci. Rep. 11, 5738 (2021).

ADS CAS PubMed PubMed Central Article Google Scholar

McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429442 (2007).

CAS PubMed Article Google Scholar

Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117, 244279 (2008).

CAS PubMed Article Google Scholar

Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 23382348 (2017).

PubMed Article Google Scholar

Weinblatt, M. E. Methotrexate in rheumatoid arthritis: A quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 16 (2013).

PubMed PubMed Central Google Scholar

Dey, M., Zhao, S. S. & Moots, R. J. Anti-TNF biosimilars in rheumatology: The end of an era?. Expert Opin. Biol. Ther. 21, 2936 (2021).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685699 (2020).

CAS PubMed Article Google Scholar

Garca, C. C., Lefvre, A. & Busnel, J.-M.R. Development of a flow cytometry-based functional assay to study anti-TNF mechanisms of action and capture donor heterogeneity. ImmunoHorizons 4, 648658 (2020).

PubMed Article CAS Google Scholar

Laffon, A. et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88, 546552 (1991).

CAS PubMed PubMed Central Article Google Scholar

Murata, K. et al. CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int. Immunol. 15, 987992 (2003).

CAS PubMed Article Google Scholar

Capsoni, F. et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res. Ther. 7, 208 (2005).

CAS PubMed PubMed Central Article Google Scholar

Leite Pereira, A. et al. Characterization of phenotypes and functional activities of leukocytes from rheumatoid arthritis patients by mass cytometry. Front. Immunol. 0, 2384 (2019).

Article CAS Google Scholar

Lin, S.-J. et al. Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15. Sci. Rep. 2020(10), 18 (2020).

Google Scholar

Schittenhelm, L., Robertson, J., Pratt, A. G., Hilkens, C. M. & Morrison, V. L. Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint. Rheumatology (Oxford) 60, 1533 (2021).

CAS Article Google Scholar

Torsteinsdttir, I., Arvidson, N. G., Hllgren, N. G. & Hkansson, L. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand. J. Immunol. 50, 433439 (1999).

PubMed Article Google Scholar

Maldonado, A. et al. Decreased effector memory CD45RA+ CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res. Ther. 5, R91 (2003).

PubMed PubMed Central Article Google Scholar

Navarro-Hernndez, R. E. et al. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis. Markers 26, 119126 (2009).

PubMed PubMed Central Article Google Scholar

Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S. & Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 36, 345350 (2007).

CAS PubMed Article Google Scholar

Klimiuk, P. A., Sierakowski, S., Domyslawska, I. & Chwiecko, J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 38, 439444 (2009).

CAS PubMed Article Google Scholar

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492 (2014).

CAS PubMed Article Google Scholar

Wijbrandts, C. A. & Tak, P. P. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin. Proc. 92, 11291143 (2017).

CAS PubMed Article Google Scholar

Schinnerling, K., Rosas, C., Soto, L., Thomas, R. & Aguilln, J. C. Humanized mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of cell-based therapies. Front. Immunol. 10, 203 (2019).

CAS PubMed PubMed Central Article Google Scholar

Koboziev, I. et al. Use of humanized mice to study the pathogenesis of autoimmune and inflammatory diseases. Inflamm. Bowel Dis. 21, 16521673 (2015).

PubMed Article Google Scholar

Rothbauer, M. et al. Establishment of a human three-dimensional chip-based chondro-synovial co-culture joint model for reciprocal cross-talk studies in arthritis research. Lab Chip 21, 4128. https://doi.org/10.1101/2021.02.19.431936 (2021).

CAS Article PubMed Google Scholar

Damerau, A. & Gaber, T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. Int. J. Mol. Sci. 21, 125 (2020).

Google Scholar

Jorgensen, C. & JSimon, M. In vitro human joint models combining advanced 3D Cell culture and cutting-edge 3D bioprinting technologies. Cells 10, 596 (2021).

PubMed PubMed Central Article Google Scholar

Edilova, M. I., Akram, A. & Abdul-Sater, A. A. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed. J. 44, 172182 (2021).

PubMed Article Google Scholar

Yamin, R. et al. High percentages and activity of synovial fluid NK cells present in patients with advanced stage active rheumatoid arthritis. Sci. Rep. 2019(9), 112 (2019).

Google Scholar

Talbot, J. et al. CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, NJ) 67, 17511759 (2015).

CAS Article Google Scholar

Vasanthi, P., Nalini, G. & Rajasekhar, G. Status of oxidative stress in rheumatoid arthritis. Int. J. Rheum. Dis. 12, 2933 (2009).

PubMed Article Google Scholar

Adhya, S. et al. Serology and immunoglobulin profile in rheumatoid arthritis. Indian J. Pathol. Microbiol. 41, 4347 (1998).

CAS PubMed Google Scholar

Yang, S., Liu, F., Wang, Q. J., Rosenberg, S. A. & Morgan, R. A. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6, e22560 (2011).

ADS CAS PubMed PubMed Central Article Google Scholar

Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A major regulator of leukocyte adhesion. Migr. Signal. Front. Immunol. 10, 1068 (2019).

CAS Article Google Scholar

Khan, S. Q., Khan, I. & Gupta, V. CD11b activity modulates pathogenesis of lupus nephritis. Front. Med. 0, 52 (2018).

Article Google Scholar

Hassan, W. A., Baraka, E. A. & Fouad, N. A. Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status. Egypt. Rheumatol. 37, 165169 (2015).

Article Google Scholar

Luo, Q. et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol. Med. Rep. 17, 32973305 (2018).

CAS PubMed Google Scholar

Liu, Y. et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin. Immunol. 137, 288295 (2010).

CAS PubMed Article Google Scholar

Wan, B. et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, 88448850 (2006).

CAS PubMed Article Google Scholar

Flores-Borja, F., Jury, E. C., Mauri, C. & Ehrenstein, M. R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 105, 1939619401 (2008).

ADS CAS PubMed PubMed Central Article Google Scholar

Gerards, A. H., de Lathouder, S., de Groot, E. R., Dijkmans, B. A. C. & Aarden, L. A. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42, 11891196 (2003).

CAS PubMed Article Google Scholar

Zamora-Atenza, C. et al. Adalimumab regulates intracellular TNF production in patients with rheumatoid arthritis. Arthritis Res. Ther. 16, R153 (2014).

PubMed PubMed Central Article CAS Google Scholar

Schuerwegh, A. J., Van Offel, J. F., Stevens, W. J., Bridts, C. H. & De Clerck, L. S. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford). 42, 541548 (2003).

CAS PubMed Article Google Scholar

Follow this link:
Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific...

New Approaches Needed To Support Digitization Of Healthcare

At the recent HIMSS conference in Helsinki, the breadth of digital solutions promising to transform healthcare was prodigious. What is also sadly evident for any seasoned observer of the sector is that the pace of change remains incredibly slow, and while digital tools have enabled many sectors to do more with less, healthcare remains largely beholden to Baumol's cost disease.

A recent project from the University of Twente suggests that for healthcare to truly achieve the benefits of digitization will require a different approach to transformation.

Digitization is about more than just the use of technology above all, its about a different way of working, and that requires vision, guts and leadership, the researchers explain.

The promises of digital healthcare are considerable, from the delivery of personalized medicine to a reduction in workload via a more preventative approach to healthcare that could also keep a lid on costs that are continuously escalating. As I argue in another article, the capacity to absorb new technologies is often a limiting factor in a sector that is nearly always stretched to breaking point, even before the pandemic exacerbated matters.

The researchers explored both the research literature and practice to try and identify ways to improve matters and accelerate the digitization of the sector. Central to their recommendations is a more proactive role from the government in driving digitization, with long-term policies needed to help set in motion the process of change. Fundamental to this is a shift in how people in the healthcare sector work.

One thing that needs to change is how we use personnel, the researchers explain. In addition to medical professionals, we must use professionals with a technical-medical background and data analysts.

The researchers argue that a key starting point is for healthcare organizations not to consider digitization as primarily a means of reducing costs. At the moment, they believe that healthcare organizations struggle to justify investing in digitization because it's not clear how they can recoup their costs. This then helps to undermine any willingness to experiment and innovate.

There are also considerable problems in terms of interoperability as few systems seem to work together or indeed exchange information effectively. The adoption of electronic patient records has been a well-known example of a digitization process beset by problems getting systems to talk to one another. Often the fragmented nature of healthcare systems means that each organization goes its own way, which hampers interoperability further.

"The entire global healthcare system had a rude awakening during the pandemic as without interoperability and definitions of data, our ability to collect information and exchange it during the early days of the pandemic was limited," Hal Woolf, President & CEO, HIMSS, explains. "Now we're in a place where people are recognizing the transactional nature of information as a critical dependecy in order for us to be able to look at public health and understand what is transpiring."

The Dutch researchers argue that for things to change, it's vital that the government take charge, as currently there is too large a gap between what government wants and what happens in practice. They believe that a multidisciplinary approach is vital for this gap to be narrowed and digitization supported.

Only by doing this do they believe that things like privacy, security, and inclusiveness can be properly addressed, with these obviously crucial for technologies like AI to make an impact. This could also help in terms of informing citizens of not only the possibilities with the digitization of healthcare but also their rights.

"It's critical that healthcare systems are able to dedicate some level of resources for the implementation of innovations, which should be somewhere between 2 and 5%," Woolf continues. "This is undoutedly a lot, but it sets aside the bandwidth for implementation and establishes a cadence in anticipation of the ongoing nature of change and innovation."

The Dutch team believes that by combining policy, infrastructure, funding, and government power then the digitization of healthcare can occur, with the aim being to ensure that technology is effectively used to ensure that healthcare is not only faster and more efficient but also that continuity and quality of care is maintained.

The pandemic showed us that many obstacles on the road towards digital care could be overcome in a short period of time," the researchers conclude. But still, the implementation of many digital applications is lagging behind. We need a change in culture, digital literacy training, and better long-term funding to ensure that digitization has a lasting impact on healthcare.

Read this article:
New Approaches Needed To Support Digitization Of Healthcare - Forbes